cas 415697-57-3|| where to buy 2-Bromo-N-(4,5-Dimethylisoxazol-3-Yl)-N-(Methoxymethyl)Benzenesulfonamide

Produktname:2-Bromo-N-(4,5-Dimethylisoxazol-3-Yl)-N-(Methoxymethyl)Benzenesulfonamide

IUPAC Name:2-bromo-N-(4,5-dimethyl-1,2-oxazol-3-yl)-N-(methoxymethyl)benzene-1-sulfonamide

: CAS：415697-57-3; Molekulare Formel：C13H15BrN2O4S; Reinheit：95%+

Packungseinheit	Verfügbarer Vorrat	Preis($)	Menge
CM429843-1g	in stock	ȖȖǆ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 415697-57-3 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:415697-57-3; Molekulare Formel:C13H15BrN2O4S; Schmelzpunkt:-; SMILES-Code:COCN(C1=NOC(C)=C1C)S(=O)(=O)C1=C(Br)C=CC=C1; Dichte:

: Katalognummer:CM429843; Molekulargewicht:375.24; Siedepunkt:; Mdl-Nr.:MFCD30185863; Lagerung:

: Isoxazoles; Isoxazole is a liquid heterocyclic compound C3H3NO isomeric with oxazole and having a penetrating odor like that of pyridine. Isoxazoles belong to an important class of five-membered aromatic heterocycles containing two electronegative heteroatoms, nitrogen and oxygen, in a 1,2-relationship and three regular sp2 carbon atoms. These molecules are found to be key components in various synthetic products in daily use and also present as a pharmacophore essential for biological activity in many drugs and bioactive natural products. In addition, isoxazoles have demonstrated their ability to exhibit hydrogen bond donor/acceptor interactions with a variety of enzymes and receptors.

: Sparsentan; CSL Vifor and Travere Therapeutics announce European Commission approves FILSPARI(sparsentan) for the treatment of IgA Nephropathy (IgAN). First non-immunosuppressive therapy for the treatment of IgAN approved in Europe.
Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin angiotensin receptor antagonist with high selectivity for the endothelin A receptor (ETAR) and the angiotensin II subtype 1 receptor (AT1R). Pre-clinical data have shown that blockade of both endothelin type A and angiotensin II type 1 pathways in forms of rare chronic kidney disease, protects podocytes, prevents glomerulosclerosis and mesangial cell proliferation, and reduces proteinuria.